Tony Mok, MD

November 1, 2016

|

By

|

Estimated Read Time:

1–2 minutes

Tony Mok has been selected by the American Society of Clinical Oncology (ASCO) as a candidate for the 2017 ASCO Board of Directors. Professor Mok is a professor in the Department of Clinical Oncology at the Chinese University of Hong Kong in Prince of Wales Hospital in Hong Kong. Professor Mok is also the Immediate-Past President of the IASLC.

About the Authors

Share this Article:

Tony Mok, MD

Recent Posts

IASLC Recommendations Define Core Standards for Molecular Tumor Boards

Atezolizumab Improves PFS, but Not OS, When Added to Chemotherapy in Older Patients With Advanced NSCLC

Zipalertinib Demonstrates Promising Results for Treatment of Patients With EGFR-Mutated NSCLC After Progression

Opening Keynote to Explore Lessons From Neoadjuvant Immunotherapy Trials in Early-Stage NSCLC

COCOON’s Prophylactic Regimen Resulted in Decreased Incidence and Severity of Dermatologic-related Adverse Events

MARIPOSA OS Data Confirms Improved Efficacy for Amivantamab Plus Lazertinib in the First Line for EGFR-mutated NSCLC

Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection

Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy

Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC

No “Known” Risk Factors: The Health Consequences of Radiation Therapy

Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging

No PFS, OS Benefit Seen in Final Results from PACIFIC-2

WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers

Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture

A Holistic Approach to Patient Care